Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Name: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Published: 2015
License: Public Domain

Novartis Pharmaceuticals · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

lung-cancer non-small-cell-lung-cancer nsclc

non-small cell lung cancer, ldk378, ceritinib, alk+, alk positive, nsclc, lung cancer, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Related documents